OPTION AGREEMENTOption Agreement • January 17th, 2014 • uniQure B.V. • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUBLICENSE AND RESEARCH AGREEMENTAgreement • January 17th, 2014 • uniQure B.V. • Pharmaceutical preparations • British Columbia
This Agreement is made and entered into this 18th day of June, 2001 by and between Xenon Genetics Inc., a corporation organized a d existing under the laws of Canada, with registered offices at Suite 100 - 2386 East Mall, Vancouver, BC, Canada V6T 1Z3 (hereinafter referred to as: “Xenon”), of the one part, and Amsterdam Molecular Therapeutics B.V., a closed limited liability company organized and existing under the laws of the Netherlands, with registered offices at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands, (hereinafter referred to as “AMT”), of the other part, the parties (hereinafter also individually referred to as “Party” and collectively as “Parties”);
UNIQURE B.V. Meibergdreef 61 Amsterdam 1105 BA, The NetherlandsuniQure B.V. • January 17th, 2014 • Pharmaceutical preparations
We refer to (1) the Collaboration and License Agreement by and between 4D Molecular Therapeutics, LLC (“4DMT”) and uniQure Biopharma B.V. dated as of the date hereof (the “CLA”), and (2) the Grant Letters by and between uniQure B.V. and each of you dated as of the date hereof (the “Option Grants”). This letter is the Commitment Letter referred to in the Introduction to the CLA.
uniQure N.V. Share Option Agreement Granted Under 2014 Share Incentive PlanShare Option Agreement • January 17th, 2014 • uniQure B.V. • Pharmaceutical preparations
uniQure N.V. Incentive Share Option Agreement Granted Under 2014 Share Incentive PlanIncentive Share Option Agreement • January 17th, 2014 • uniQure B.V. • Pharmaceutical preparations
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN 4D MOLECULAR THERAPEUTICS, LLC AND UNIQURE BIOPHARMA B.V. JANUARY 17, 2014Collaboration and License Agreement • January 17th, 2014 • uniQure B.V. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is entered into as of January 17, 2014 (the “Effective Date”), by and between 4D Molecular Therapeutics, LLC, a limited liability company organized and existing under the laws of the State of Delaware and having a principal office located at 19 Rima Court, Danville, CA 94526 (“4DMT”), and uniQure biopharma B.V., a corporation organized and existing under the laws of The Netherlands and having a principal office located at Meibergdreef 61, 1105 BA Amsterdam, The Netherlands (“uniQure”).
